When both ovaries are surgically removed, the body's estrogen doesn't fade gradually—it plummets. A new study published in the journal Menopause reveals what many women going through surgical menopause already know: the symptoms that follow can be far more severe than what women experience during natural menopause.
The difference matters deeply, because genitourinary syndrome of menopause (GSM) already affects a significant portion of the postmenopausal population. This chronic condition, caused by the loss of estrogen and affecting the lower urinary tract and genital tissues, strikes between 27 and 84 percent of women after menopause. Yet it remains largely unaddressed in routine medical care—a gap that becomes even more critical for women whose menopause arrives suddenly due to ovary removal.
Researchers studied more than 400 postmenopausal women to compare GSM symptoms in those who underwent surgical menopause versus natural menopause. The findings were striking. Women whose ovaries had been surgically removed reported significantly higher frequencies of the symptoms most disruptive to daily life: vaginal dryness, pain during intercourse and urination, reduced sexual desire, postcoital bleeding, and increased urinary frequency. The clinical exam scores measuring GSM severity were also markedly worse in the surgical menopause group.
The distinction lies in timing and intensity. Natural menopause unfolds over years, giving the body time to adjust to gradually declining hormones. Surgical menopause—the immediate removal of both ovaries—creates a hormone cliff. This sudden deprivation hits the genital and urinary tissues hard, triggering symptoms that not only disrupt quality of life but often go unrecognized and untreated.
Dr. Stephanie Faubion, medical director for The Menopause Society, underscores what the research makes clear: "GSM symptoms and exam findings were worse in women who experienced menopause due to removal of both ovaries compared to those who underwent menopause naturally." Given how prevalent and undertreated GSM already is, she notes, "in women with surgical menopause, this may be even more critical and should prompt early evaluation and treatment of symptoms."
The findings point to a practical path forward on two fronts. First, healthcare providers need to actively ask midlife women—especially those facing or having undergone ovary removal—about GSM symptoms rather than waiting for patients to volunteer information. Second, the research adds weight to a growing medical preference for ovary-conserving approaches during hysterectomy whenever it's clinically safe to do so.
For women already living with surgical menopause, the message is clear: the symptoms affecting your quality of life are not inevitable or simply something to endure. They're a recognized medical condition, increasingly well understood by researchers and clinicians who can help. Early intervention makes a real difference, and knowing that your symptoms may be more severe than those experienced by women in natural menopause can help you advocate for the care you need.